MyFinsight
Home
Blog
About
Proceeds from maturities
of investments in...
$43,536K
Proceeds from purchases
under the employee...
$202K
(7.45%↑ Y/Y)
Other financing
activities, net
$63K
(107.33%↑ Y/Y)
Net cash provided by
investing activities
$29,631K
(-93.34%↓ Y/Y)
Net cash provided by
(used in) financing...
$144K
(100.05%↑ Y/Y)
Canceled cashflow
$13,905K
Canceled cashflow
$121K
Net increase
(decrease) in cash, cash...
-$32,315K
(-135.55%↓ Y/Y)
Canceled cashflow
$29,775K
Trade receivables,
net
-$8,222K
(92.26%↑ Y/Y)
Prepaids and other
current and non-current...
-$7,639K
(-979.06%↓ Y/Y)
Stock-based compensation
expense
$2,583K
(-76.07%↓ Y/Y)
Accounts payable
$1,689K
(102.76%↑ Y/Y)
Depreciation and
amortization
$862K
(-58.20%↓ Y/Y)
Inventory
-$437K
(-102.37%↓ Y/Y)
(gain) loss on sale
transactions, net (note 6)
-$311K
(-100.09%↓ Y/Y)
Purchases of investments
in marketable...
$13,897K
(-32.95%↓ Y/Y)
Other investing
activities, net
$8K
(-97.36%↓ Y/Y)
Repayment and redemption
of 2026...
$121K
(-99.95%↓ Y/Y)
Net cash used in
operating activities
-$62,090K
(14.31%↑ Y/Y)
Canceled cashflow
$21,743K
Tsa related
operating assets and...
$38,871K
(268.55%↑ Y/Y)
Net income (loss)
-$20,631K
(-108.55%↓ Y/Y)
Other non-cash
adjustments, net
-$12,498K
(-601.93%↓ Y/Y)
Accrued compensation
-$5,332K
(27.25%↑ Y/Y)
something is missing
-$4,485K
Accrued and other
current and non-current...
-$1,282K
(91.40%↑ Y/Y)
Accrued rebates, fees
and reserves
-$734K
(98.92%↑ Y/Y)
Back
Back
Cash Flow
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)
source: myfinsight.com